Evidence based responsible use of antibiotics in companion animals. ([2013])

• Record Type: Book
• Further Information: Note: Henri-Jean Boulouis [and seven others].
• Authors: Boulouis, Henri-Jean; Caney, Sarah; Cotard, Jean-Pierre; Dupre, Gilles; Farca, Anna Maria; Fontaine, Jacques; Kietzmann, Manfred; Lechowski, Roman
• Contents: Front Cover; Evidence Based Responsible Use of Antibiotics in Companion Animals; Copyright Page; Table of Contents; Evidence Based Responsible Use of Antibiotics in Companion Animals: The REQUEST Group contribution with a special fluoroquinolones; Foreword; References; Chapter 1. Introduction to the Responsible Use of Antibiotics in Companion Animals; Definition of companion animal; Companion animals in Europe; Common infectious diseases; Antibiotic consumption in 2012; Threat of development of antimicrobial resistance; Responsible use of fluoroquinolones; References. Chapter 2. Building an EBVM Methodology Dedicated to the Responsible Use of AntibioticsSetting the size of the working group; Limitation of strict EBVM methodology and available alternatives; REQUEST proprietary methodology overview; Consensus meetings in practice; Elaboration of REQUEST Guidelines; Grading REQUEST Guidelines; References; Chapter 3. Critical Review of Fluoroquinolone Susceptibility Studies; Purpose of the critical review of susceptibility studies; Inclusion and exclusion criteria for susceptibility studies; Grading of collected susceptibility data. Origin of strains and grading of source dataAssessed pathogenic strains; Assessed fluoroquinolones; Available data from susceptibility studies; Comments regarding available susceptibility data; References; Chapter 4. Critical Review of Fluoroquinolone Pharmacokinetic Studies; Purpose of the critical review of pharmacokinetic studies; Inclusion and exclusion criteria for pharmacokinetic studies; Available data from pharmacokinetic studies; Grading of collected pharmacokinetic data; Comments regarding available data; References. Chapter 5. Critical Review of Fluoroquinolone Clinical Toxicity in CatsPurpose of the critical review of toxicology studies in cats; Inclusion and exclusion criteria for toxicology studies in cats; Toxicology data; Rationale for the focus on retinal toxicity in cats; Comments regarding retinal toxicity data; Specific caution regarding enrofloxacin retinal toxicity in cats; References; Chapter 6. Critical Review of Fluoroquinolone Adverse Effects in Dogs; Purpose of the critical review of adverse effects in dogs; Inclusion and exclusion criteria for studies in dogs. Available study data on adverse effects in dogsMost significant or common adverse effects; Therapeutic or supratherapeutic dosage impact; Comments regarding data on adverse effects in dogs; References; Chapter 7. Responsible Use of Fluoroquinolones in Urinary Tract Infections in Dogs; Rationale for special focus on UTI in dogs; Inclusion and exclusion criteria for UTI studies; Available data from UTI studies; Therapeutic strategy for UTI in dogs; REQUEST diagnosis and therapeutic algorithm for UTI in dogs; Comments on the available literature concerning UTI in dogs.
• Publisher Details: France : Elsevier Health Sciences
• Publication Date: 2013
• Extent: 1 online resource (130 pages)
• Subjects: 636.08951; Veterinary drugs; Veterinary medicine; Veterinary pharmacology; TECHNOLOGY & ENGINEERING -- Agriculture -- Animal Husbandry; Veterinary drugs; Veterinary medicine; Veterinary pharmacology; Electronic books
• Languages: English
• ISBNs: 9782294742590; 2294742591; 1336264551; 9781336264557
• Related ISBNs: 9782294742583; 2294742583
• Notes: Note: Includes bibliographical references (pages 110-129).; Note: Print version record.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.